This is a data-driven look at Glaxosmithkline Pharmaceuticals Ltd. (GLAXO), spanning financial performance, valuation, and shareholding trends.
Glaxo Pharma Revenue Trend
Revenue at Glaxosmithkline Pharmaceuticals Ltd. slipped to ₹3,822 Cr in FY2026, a 1.9% drop from ₹3,895 Cr in FY2025.
A 3.1% CAGR over 13 years isn't much to write home about. Revenue at Glaxosmithkline Pharmaceuticals Ltd. has crept up from ₹2,563 Cr to ₹3,822 Cr in that span.
With ₹3,822 Cr in annual revenue, Glaxosmithkline Pharmaceuticals Ltd. sits among the mid-sized players in the pharmaceuticals space.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹3,822 Cr | -1.9% |
| FY2025 | ₹3,895 Cr | +8.9% |
| FY2024 | ₹3,576 Cr | +8.1% |
| FY2021 | ₹3,309 Cr | +2.6% |
| FY2020 | ₹3,224 Cr | — |
View Glaxosmithkline Pharmaceuticals Ltd.'s full 10-year revenue trend with CAGR analysis →
Glaxo Pharma Profitability
Net profit for Glaxosmithkline Pharmaceuticals Ltd. came in at ₹1,036 Cr in FY2026, up 11.7% from the ₹928 Cr earned in FY2025.
Margins improved too: net margin climbed from 23.8% in FY2025 to 27.1% in FY2026.
Diluted EPS for FY2026 rose to ₹61.15, up from ₹54.76 in FY2025.
Is Glaxo Pharma Undervalued
Based on the P/E Ratio method, Glaxosmithkline Pharmaceuticals Ltd.'s fair value works out to ₹4,093, 69.1% upside from the current price.
Shares of Glaxosmithkline Pharmaceuticals Ltd. currently trade at ₹2,420.50.
Craytheon also works out intrinsic value through the EPS Growth and DCF models, with the full breakdown and assumptions available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹4,093 | 69.1% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Glaxosmithkline Pharmaceuticals Ltd. with detailed assumptions →
Glaxo Pharma Shareholding Pattern
Promoter holding stands at 75.0%, unchanged over recent quarters.
Foreign institutional investors (FIIs) owned 4.6% as of March 2026, down from 4.9% a year earlier.
As of March 2026, domestic institutional investors (DIIs) held 7.7%, down from 7.7% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 75.0% | 4.6% | 7.7% | 12.7% |
| Dec 2025 | 75.0% | 4.6% | 7.7% | 12.7% |
| Sep 2025 | 75.0% | 4.8% | 7.8% | 12.4% |
| Jun 2025 | 75.0% | 4.9% | 7.7% | 12.4% |
Track quarterly shareholding changes for Glaxosmithkline Pharmaceuticals Ltd. →
Glaxo Pharma Balance Sheet
Proportional view as of 13 Jul 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2026 total assets: ₹43.24B (up 5.3% YoY from ₹41.08B).
Top categories: Cash & ST Investments (57.7%), Other Assets (18.9%), Inventories (10.6%).
Of the ₹43.24B in liabilities and equity, 52.4% is shareholder equity, 0.8% is interest-bearing debt, and 46.8% is operating liabilities. Over the year, debt is up 234.4% and equity is up 16.2%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 24.93B |
| Receivables | 2.73B |
| Inventories | 4.58B |
| Property, Plant & Equipment | 2.75B |
| Investments | 8.67M |
| Intangibles & Goodwill | 65.56M |
| Other Assets | 8.18B |
| Category | Value |
|---|---|
| Equity | 22.67B |
| Short-term Debt | 159.99M |
| Long-term Debt | 172.73M |
| Trade Payables | 5.70B |
| Other Liabilities | 14.53B |
What Stands Out About Glaxo Pharma
Pulling these threads together, here's where Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) stands as a pharmaceuticals investment opportunity.
FY2026 revenue came in at ₹3,822 Cr, down 1.9% year-over-year.
Over the past 13 years, revenue has compounded at 3.1% annually.
Profitability remains solid, with a 27.1% net margin and net income of ₹1,036 Cr.
The P/E Ratio model implies 69.1% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Glaxosmithkline Pharmaceuticals Ltd..